Müller cell-derived VEGF is a significant contributor to retinal neovascularization

Vascular endothelial growth factor (VEGF-A) is a major pathogenic factor and a therapeutic target for age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity. Despite intensive effort in the field, the cellular mechanisms of VEGF action remain virtually uninvestigated....

Full description

Saved in:
Bibliographic Details
Published inThe Journal of pathology Vol. 219; no. 4; pp. 446 - 454
Main Authors Bai, Yanyan, Ma, Jian-xing, Guo, Junjing, Wang, Juanjuan, Zhu, Meili, Chen, Ying, Le, Yun-Zheng
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.12.2009
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Vascular endothelial growth factor (VEGF-A) is a major pathogenic factor and a therapeutic target for age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity. Despite intensive effort in the field, the cellular mechanisms of VEGF action remain virtually uninvestigated. This situation makes it difficult to design cellular target-based therapeutics for these diseases. In light of the recent finding that VEGF is a potential neurotrophic factor, revealing the cellular mechanisms of VEGF action becomes necessary to preserve its beneficial effect and inhibit its pathological function in long-term anti-VEGF therapeutics for ocular vascular diseases. We therefore generated conditional VEGF knockout mice with an inducible Cre/lox system and determined the significance of Müller cell-derived VEGF in retinal development and maintenance and ischaemia-induced neovascularizartion and vascular leakage. Retinal development in the conditional VEGF knockout mice was analysed by examining retinal and choroidal vasculatures and retinal morphology and function. Ischaemia-induced retinal neovascularization and vascular leakage in the conditional VEGF knockout mice were analysed with fluorescein angiography, quantification of proliferative neovascular cells, immunohistochemistry, and immunoblotting using an oxygen-induced retinopathy model. Our results demonstrated that disruption of Müller cell-derived VEGF resulted in no apparent defects in retinal and choroidal vasculatures and retinal morphology and function, significant inhibition of the ischaemia-induced retinal neovascularization and vascular leakage, and attenuation of the ischaemia-induced breakdown of the blood-retina barrier. These results suggest that the retinal Müller cell-derived VEGF is a major contributor to ischaemia-induced retinal vascular leakage and pre-retinal and intra-retinal neovascularization. The observation that a significant, but not complete, reduction of VEGF in the retina does not cause detectable retinal degeneration suggests that appropriate doses of anti-VEGF agents may be important to the safe treatment of retinal vascular diseases. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Bibliography:http://dx.doi.org/10.1002/path.2611
JDRF - No. 5-2005-1292
NIH - No. P20 RR17703; No. P20 RR024215; No. P30 EY12190; No. EY015650; No. EY012231
ark:/67375/WNG-TJ33FSG9-9
ArticleID:PATH2611
ADA - No. 1-06-RA-76
The authors declare that there are no conflicts of interest relevant to this study.
AHAF - No. M2008-059
OCAST - No. HR09-058
istex:31558102C6F226DF2DAF738D4FDA61A795EBAA93
FFB - No. BR-CMM-0808-0453-UOK
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-3417
1096-9896
DOI:10.1002/path.2611